SANOFI SA INHABER EO 2/ FR0000120578 /
11/6/2024 4:05:41 PM | Chg. -1.0800 | Volume | Bid9:59:59 PM | Ask9:59:59 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
94.9800EUR | -1.12% | 340 Turnover: 32,529.6000 |
-Bid Size: - | -Ask Size: - | 119.88 bill.EUR | 3.93% | 22.19 |
GlobeNewswire
9/2
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...
GlobeNewswire
8/26
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
8/14
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
8/13
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/12
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire
8/8
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire
8/6
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire
8/1
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
7/31
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire
7/25
Press Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswire
7/25
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
GlobeNewswire
7/24
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...
GlobeNewswire
7/18
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, Accord...